364 related articles for article (PubMed ID: 12897778)
1. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.
Matsunaga T; Takemoto N; Sato T; Takimoto R; Tanaka I; Fujimi A; Akiyama T; Kuroda H; Kawano Y; Kobune M; Kato J; Hirayama Y; Sakamaki S; Kohda K; Miyake K; Niitsu Y
Nat Med; 2003 Sep; 9(9):1158-65. PubMed ID: 12897778
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
Matsunaga T; Fukai F; Miura S; Nakane Y; Owaki T; Kodama H; Tanaka M; Nagaya T; Takimoto R; Takayama T; Niitsu Y
Leukemia; 2008 Feb; 22(2):353-60. PubMed ID: 17972943
[TBL] [Abstract][Full Text] [Related]
3. Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state.
Layani-Bazar A; Skornick I; Berrebi A; Pauker MH; Noy E; Silberman A; Albeck M; Longo DL; Kalechman Y; Sredni B
Cancer Res; 2014 Jun; 74(11):3092-103. PubMed ID: 24699624
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Mahlknecht U; Schönbein C
Haematologica; 2008 Mar; 93(3):443-6. PubMed ID: 18268283
[TBL] [Abstract][Full Text] [Related]
5. [Molecular targeting therapy by anti-VLA-4 monoclonal antibodies for AML].
Niitsu Y; Matsunaga T
Rinsho Ketsueki; 2005 Mar; 46(3):198-201. PubMed ID: 16447714
[No Abstract] [Full Text] [Related]
6. Role of VLA-4 and VLA-5 in ex vivo maintenance of human and pig hematopoiesis in human stroma-supported long-term cultures.
Giovino MA; Wang H; Sykes M; Yang YG
Exp Hematol; 2005 Mar; 33(3):363-70. PubMed ID: 15730860
[TBL] [Abstract][Full Text] [Related]
7. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow.
Korah R; Boots M; Wieder R
Cancer Res; 2004 Jul; 64(13):4514-22. PubMed ID: 15231661
[TBL] [Abstract][Full Text] [Related]
8. Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1.
Zhang X; Groopman JE; Wang JF
J Cell Physiol; 2005 Jan; 202(1):205-14. PubMed ID: 15389531
[TBL] [Abstract][Full Text] [Related]
9. Human acute myeloid leukaemia cells express adhesion proteins and bind to bone marrow fibroblast monolayers and extracellular matrix proteins.
Kortlepel K; Bendall LJ; Gottlieb DJ
Leukemia; 1993 Aug; 7(8):1174-9. PubMed ID: 8350618
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
11. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse.
Shalapour S; Hof J; Kirschner-Schwabe R; Bastian L; Eckert C; Prada J; Henze G; von Stackelberg A; Seeger K
Haematologica; 2011 Nov; 96(11):1627-35. PubMed ID: 21828124
[TBL] [Abstract][Full Text] [Related]
12. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
[TBL] [Abstract][Full Text] [Related]
13. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
Nieborowska-Skorska M; Slupianek A; Skorski T
Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
[TBL] [Abstract][Full Text] [Related]
14. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
Hong Z; Xiao M; Yang Y; Han Z; Cao Y; Li C; Wu Y; Gong Q; Zhou X; Xu D; Meng L; Ma D; Zhou J
Carcinogenesis; 2011 Oct; 32(10):1550-8. PubMed ID: 21803735
[TBL] [Abstract][Full Text] [Related]
15. PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells.
Quaranta MT; Spinello I; Testa U; Mariani G; Diverio D; Foà R; Peschle C; Labbaye C
Oncogene; 2006 Jan; 25(3):399-408. PubMed ID: 16158049
[TBL] [Abstract][Full Text] [Related]
16. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.
Knuefermann C; Lu Y; Liu B; Jin W; Liang K; Wu L; Schmidt M; Mills GB; Mendelsohn J; Fan Z
Oncogene; 2003 May; 22(21):3205-12. PubMed ID: 12761490
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4.
Okigami H; Takeshita K; Tajimi M; Komura H; Albers M; Lehmann TE; Rölle T; Bacon KB
Eur J Pharmacol; 2007 Mar; 559(2-3):202-9. PubMed ID: 17234179
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+).
Weimar IS; Miranda N; Muller EJ; Hekman A; Kerst JM; de Gast GC; Gerritsen WR
Exp Hematol; 1998 Aug; 26(9):885-94. PubMed ID: 9694510
[TBL] [Abstract][Full Text] [Related]
19. HGF protects corneal epithelial cells from apoptosis by the PI-3K/Akt-1/Bad- but not the ERK1/2-mediated signaling pathway.
Kakazu A; Chandrasekher G; Bazan HE
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3485-92. PubMed ID: 15452053
[TBL] [Abstract][Full Text] [Related]
20. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
